We have located links that may give you full text access.
Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumors: A cost-effectiveness study.
British Journal of Clinical Pharmacology 2019 May 22
BACKGROUND: Patients with metastatic gastro intestinal stromal tumors (GIST) are treated in first line with the oral tyrosine kinase inhibitor, imatinib, until progressive disease. With this fixed dosing regimen, only approximately 40% of patients reach adequate plasma levels within the therapeutic index. Therapeutic drug monitoring (TDM) is an solution to reach plasma levels within the therapeutic index. However introducing TDM will also increase costs, due to prolonged imatinib use and laboratory costs. The aim of this study was to evaluate the cost-effectiveness of TDM in patients with metastatic/unresectable GIST treated with imatinib as a first line treatment, compared with fixed dosing.
METHODS: A survival model was created to simulate progression, mortality and treatment costs over a 5 year time horizon, comparing fixed dosing versus TDM guided dosing. The outcomes measured were treatments costs, life-years and quality-adjusted life-years.
RESULTS: Total costs over 5 years time horizon were estimated to be €106.994,85 and €150.477,08 for fixed dosing versus TDM guided dosing, respectively. A QALY gain of 0,74 (0,66 - 0,90 95% CI) was estimated with TDM guided dosing compared to fixed dosing. An average incremental cost-effectiveness ratio of €58.785,70 per QALY gained was found, mainly caused by longer use and higher dosages of imatinib.
CONCLUSION: Based on the currently available data, this analysis suggests that TDM guided dosing may be a cost-effective intervention for patients with metastatic/unresectable GIST treated with imatinib which will be improved when imatinib losses its patency.
METHODS: A survival model was created to simulate progression, mortality and treatment costs over a 5 year time horizon, comparing fixed dosing versus TDM guided dosing. The outcomes measured were treatments costs, life-years and quality-adjusted life-years.
RESULTS: Total costs over 5 years time horizon were estimated to be €106.994,85 and €150.477,08 for fixed dosing versus TDM guided dosing, respectively. A QALY gain of 0,74 (0,66 - 0,90 95% CI) was estimated with TDM guided dosing compared to fixed dosing. An average incremental cost-effectiveness ratio of €58.785,70 per QALY gained was found, mainly caused by longer use and higher dosages of imatinib.
CONCLUSION: Based on the currently available data, this analysis suggests that TDM guided dosing may be a cost-effective intervention for patients with metastatic/unresectable GIST treated with imatinib which will be improved when imatinib losses its patency.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app